Diabetology International最新文献_第6页

Severe periodontal disease in Japanese patients with high HbA1c levels: a cross-sectional study. HbA1c 水平较高的日本患者的严重牙周病：一项横断面研究。

IF 1.3

Diabetology International Pub Date : 2024-05-28 eCollection Date: 2024-07-01 DOI: 10.1007/s13340-024-00732-7

Noboru Kurinami, Kenji Ashida, Seigo Sugiyama, Yoko Morito, Akira Yoshida, Kunio Hieshima, Fumio Miyamoto, Keizo Kajiwara, Katsunori Jinnouchi, Hideaki Jinnouchi, Masatoshi Nomura

{"title":"Severe periodontal disease in Japanese patients with high HbA1c levels: a cross-sectional study.","authors":"Noboru Kurinami, Kenji Ashida, Seigo Sugiyama, Yoko Morito, Akira Yoshida, Kunio Hieshima, Fumio Miyamoto, Keizo Kajiwara, Katsunori Jinnouchi, Hideaki Jinnouchi, Masatoshi Nomura","doi":"10.1007/s13340-024-00732-7","DOIUrl":"10.1007/s13340-024-00732-7","url":null,"abstract":"Objective: This study aimed to investigate the relationship between plasma glucose profiles and periodontal disease (PD) severity in men and women.Methods: We conducted a cross-sectional cohort study, enrolling all eligible patients with type 2 diabetes mellitus (T2DM) who regularly visited the outpatient department.Results: Patients were divided into severe and non-severe PD groups. The severe PD group showed a male predominance and significantly higher hemoglobin A1c (HbA1c) levels than the non-severe PD group. The optimal HbA1c cutoff value on the receiver operating characteristic curve for predicting severe PD was 7.3% [56 mmol/mol] (sensitivity, 52%; specificity, 73%; P = 0.01). Multivariate logistic regression revealed that male sex (odds ratio [OR], 2.75; 95% confidence interval [CI], 1.19-6.34; P = 0.01) and higher HbA1c levels (OR, 3.09; 95% CI, 1.42-6.70; P < 0 .01) were independently and significantly associated with the presence of severe PD. The prevalence rates of severe PD in patients with HbA1c levels < 7.3% [56 mmol/mol] and HbA1c levels ≥ 7.3% [56 mmol/mol] were 17.4% and 53.3% in women, and 50.0% and 66.7% in men, respectively.Conclusions: Men with T2DM had a high risk of severe PD independent of HbA1c levels. Plasma glucose management may be crucial for maintaining periodontal health in T2DM patients, particularly in women.","PeriodicalId":11340,"journal":{"name":"Diabetology International","volume":"15 3","pages":"562-568"},"PeriodicalIF":1.3,"publicationDate":"2024-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11291773/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141888778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Innovations and applications of ketone body monitoring in diabetes care. 酮体监测在糖尿病护理中的创新和应用。

IF 1.3

Diabetology International Pub Date : 2024-05-28 eCollection Date: 2024-07-01 DOI: 10.1007/s13340-024-00735-4

Naoki Sakane

{"title":"Innovations and applications of ketone body monitoring in diabetes care.","authors":"Naoki Sakane","doi":"10.1007/s13340-024-00735-4","DOIUrl":"10.1007/s13340-024-00735-4","url":null,"abstract":"Ketone bodies, comprising β-hydroxybutyric acid (BHB), acetoacetate (AcAc), and acetone, play a vital role as essential energy substrates. In individuals with diabetes, ketone bodies can be elevated under various conditions, including diabetic ketoacidosis, use of sodium-glucose transporter type 2 (SGLT2) inhibitors, and extreme carbohydrate restriction. There are three methods for measuring ketone bodies. Urine ketone analysis (AcAc) is a standard clinical test, whereas blood ketone testing (BHB+AcAc) is valuable in identifying or resolving diabetic ketoacidosis. Recently, technology for measuring breath acetone has been introduced, which provides an easy means of monitoring ketogenic diets in obese individuals. The basic breath alcohol detector also reacts with breath acetone. Therefore, it is important for professional drivers taking SGLT2 inhibitors to be cautious as workplace breath alcohol detectors may show false-positive results. Conversely, if a positive result is obtained, a detailed examination of ketosis is necessary. This review provides an overview of ketone body measurements in individuals with diabetes.","PeriodicalId":11340,"journal":{"name":"Diabetology International","volume":"15 3","pages":"370-378"},"PeriodicalIF":1.3,"publicationDate":"2024-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11291811/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141888775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pseudo-nephropathy and hyper-excretion of urinary C-peptide: an overlooked adverse effect of an angiotensin receptor-neprilysin inhibitor (ARNI). 假性肾病和尿 C 肽分泌过多：血管紧张素受体-肾素抑制剂 (ARNI) 被忽视的不良反应。

IF 1.3

Diabetology International Pub Date : 2024-05-28 eCollection Date: 2024-07-01 DOI: 10.1007/s13340-024-00730-9

Yoshito Itoh, Shigehito Suzuki, Ryohei Mineo, Sho Sasaki, Sachiko Tamba, Takuya Sugiyama, Koji Yamamoto

{"title":"Pseudo-nephropathy and hyper-excretion of urinary C-peptide: an overlooked adverse effect of an angiotensin receptor-neprilysin inhibitor (ARNI).","authors":"Yoshito Itoh, Shigehito Suzuki, Ryohei Mineo, Sho Sasaki, Sachiko Tamba, Takuya Sugiyama, Koji Yamamoto","doi":"10.1007/s13340-024-00730-9","DOIUrl":"10.1007/s13340-024-00730-9","url":null,"abstract":"Sacubitril/valsartan, which is a combined angiotensin receptor-neprilysin inhibitor (ARNI), is used for the treatment of chronic heart failure and hypertension. Substrates of neprilysin are numerous, and the systemic effects of an ARNI remain to be determined. Increased urinary C-peptide (UCPR) and urinary albumin (UAlb) excretion has been reported with the use of an ARNI, but the mechanism is still unknown. We report an 84-year-old man with type 2 diabetes and hypertension. His UAlb and UCPR excretion and (to a lesser degree) the estimated glomerular filtration rate were increased after ARNI administration. They returned to basal levels after discontinuing ARNI administration. There was little or no change in glycemic control. Therefore, increased glomerular permeability and filtration could partially explain how neprilysin inhibition led to an elevation in UCPR excretion, in addition to other mechanisms, such as impairment of the renal ability to degrade C-peptide. Physicians must be cautious when interpreting the insulin secretion capability by UCPR and nephropathy by UAlb in ARNI-treated patients with diabetes.","PeriodicalId":11340,"journal":{"name":"Diabetology International","volume":"15 3","pages":"616-620"},"PeriodicalIF":1.3,"publicationDate":"2024-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11291816/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141888777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Naming hypoglycemia: a narrative tool for young people with type 1 diabetes and their families. 为低血糖命名：1 型糖尿病青少年及其家庭的叙事工具。

IF 1.3

Diabetology International Pub Date : 2024-05-27 eCollection Date: 2024-07-01 DOI: 10.1007/s13340-024-00731-8

Francisco Sobral do Rosário, Marta Soares, Filipe Mesquita, João Filipe Raposo

{"title":"Naming hypoglycemia: a narrative tool for young people with type 1 diabetes and their families.","authors":"Francisco Sobral do Rosário, Marta Soares, Filipe Mesquita, João Filipe Raposo","doi":"10.1007/s13340-024-00731-8","DOIUrl":"10.1007/s13340-024-00731-8","url":null,"abstract":"Objective: Hypoglycemia constitutes a communication barrier between youth with type 1 diabetes, their family members and health professionals. A narrative tool may contribute to a more effective communication.Methods: Semi-structured interviews with six open-ended questions using narrative techniques collect and analyze (thematic and comparative analysis) different ways of \"naming\" the lived experience of hypoglycemia.Results: 103 participants, 40 with type 1 Diabetes aged 10-18 years (17 female), 63 relatives (40 female). Group 1 (G1), 10-14 years old (n = 21), Group 2 (G2), 15-18 years old (n = 19), Group 3 (G3) relatives, 30-59 years old. G3 was divided, G3.1: female (n = 42) and G3.2: male (n = 21).G1 and G2 presents greater attention to symptoms. G1 refers a greater need for help, G2 emphasizes autonomy. G2 and G3 describes better the medical protocol. G1 and G2 refer more topics such as \"discomfort\", \"frustration\", \"obligation\", \"difficulty in verbalizing\", G3 refers to \"gilt\", \"fear\" and \"responsibility\". G3.1 refer more \"symptoms\", \"responsibility\", \"fault\", \"incapacity\".Conclusions: A narrative tool enhances the singularity of a common experience, proving itself useful to adolescents, relatives, and healthcare professionals.Practice implications: In addition to gathering information that is usually acquired empirically, a narrative tool exposes knowledge gaps and may allow implementing intervention strategies.","PeriodicalId":11340,"journal":{"name":"Diabetology International","volume":"15 3","pages":"550-561"},"PeriodicalIF":1.3,"publicationDate":"2024-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11291804/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141888776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances in basic research on glucagon and alpha cells. 胰高血糖素和α细胞基础研究的进展。

IF 1.3

Diabetology International Pub Date : 2024-02-26 eCollection Date: 2024-07-01 DOI: 10.1007/s13340-024-00696-8

Yoshitaka Hayashi

{"title":"Advances in basic research on glucagon and alpha cells.","authors":"Yoshitaka Hayashi","doi":"10.1007/s13340-024-00696-8","DOIUrl":"10.1007/s13340-024-00696-8","url":null,"abstract":"The regulation of plasma amino acid levels by glucagon in humans first attracted the attention of researchers in the 1980s. Recent basic research using animal models of glucagon deficiency suggested that a major physiological role of glucagon is the regulation of amino acid metabolism rather than to increase blood glucose levels. In this regard, novel feedback regulatory mechanisms that are mediated by glucagon and amino acids have recently been described between islet alpha cells and the liver. Increasingly, hyperglucagonemia in humans with diabetes and/or nonalcoholic fatty liver diseases is reported to likely be a compensatory response to hepatic glucagon resistance. Severe glucagon resistance due to a glucagon receptor mutation in humans causes hyperaminoacidemia and islet alpha cell expansion combined with pancreatic hypertrophy. Notably, a recent report showed that the restoration of glucagon resistance by liver transplantation resolved not only hyperglucagonemia, but also pancreatic hypertrophy and other metabolic disorders. The mechanisms that regulate islet cell proliferation by amino acids largely remain unelucidated. Clarification of such mechanisms will increase our understanding of the pathophysiology of diseases related to glucagon.","PeriodicalId":11340,"journal":{"name":"Diabetology International","volume":"15 3","pages":"348-352"},"PeriodicalIF":1.3,"publicationDate":"2024-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11291817/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141891543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Acknowledgement to the Reviewers. 向审稿人致谢。

IF 2.2

Diabetology International Pub Date : 2024-01-12 eCollection Date: 2024-01-01 DOI: 10.1007/s13340-023-00690-6

引用次数: 0

Prevalence and characteristics of diabetic symmetric sensorimotor polyneuropathy in Japanese patients with type 2 diabetes: the Japan Diabetes Complication and its Prevention Prospective study (JDCP study 10). 日本 2 型糖尿病患者中糖尿病对称性感觉运动多发性神经病的患病率和特征：日本糖尿病并发症及其预防前瞻性研究（JDCP 研究 10）。

IF 1.3

Diabetology International Pub Date : 2024-01-12 eCollection Date: 2024-01-01 DOI: 10.1007/s13340-023-00678-2

Hideki Kamiya, Tatsuhito Himeno, Atsuko Watarai, Masayuki Baba, Rimei Nishimura, Naoko Tajima, Jiro Nakamura

{"title":"Prevalence and characteristics of diabetic symmetric sensorimotor polyneuropathy in Japanese patients with type 2 diabetes: the Japan Diabetes Complication and its Prevention Prospective study (JDCP study 10).","authors":"Hideki Kamiya, Tatsuhito Himeno, Atsuko Watarai, Masayuki Baba, Rimei Nishimura, Naoko Tajima, Jiro Nakamura","doi":"10.1007/s13340-023-00678-2","DOIUrl":"10.1007/s13340-023-00678-2","url":null,"abstract":"Aim/introduction: This study aims to investigate the prevalence and characteristics of diabetic symmetric sensorimotor polyneuropathy (DSPN) in patients with type 2 diabetes registered in the Japan Diabetes Complication and its Prevention Prospective (JDCP) study.Materials and methods: In the study, 6338 patients with diabetes who had been treated by diabetes specialists were registered in 2007-2009. Of these, patients with type 2 diabetes who could be evaluated for DSPN were analyzed using t test, chi-square test, and logistic regression analyses. DSPN was diagnosed using the Simple Diagnostic Criteria for Diabetic Polyneuropathy proposed by the Diabetic Neuropathy Study Group in Japan.Results: Of the total participants, 5451 patients (mean age 61.4 years old and duration of diabetes 10.8 years) were analyzed. Based on the criteria, 35.8% of patients were diagnosed with DSPN. The prevalence of sensory symptoms was 25.8%. The following factors increased risk for DSPN: age [odds ratio (OR) 1.57, 95% confidence intervals (CI) 1.42-1.73], duration of diabetes (OR 1.32, 95% CI 1.21-1.43), body mass index (OR 1.19, 95% CI 1.09-1.30), systolic blood pressure (OR 1.06, 95% CI 1.01-1.10), hemoglobin A1c (OR 1.15, 95% CI 1.09-1.22), biguanides (OR 1.22, 95% CI 1.06-1.39), and insulin therapy (OR 1.59, 95% CI 1.36-1.84). The following factors decreased risk for DSPN: total cholesterol (OR 0.98, 95% CI 0.96-1.00) and exercise therapy (OR 0.85, 95% CI 0.73-0.98).Conclusions: The baseline survey clarified the prevalence and characteristics of DSPN in Japanese patients with type 2 diabetes. The survey also revealed the risk factors of DSPN.","PeriodicalId":11340,"journal":{"name":"Diabetology International","volume":"15 1","pages":"19-27"},"PeriodicalIF":1.3,"publicationDate":"2024-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10800318/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139541853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effectiveness of insulin degludec/liraglutide versus insulin degludec/insulin aspart in Japanese patients with type 2 diabetes 日本 2 型糖尿病患者使用德谷肽胰岛素/利拉鲁肽与德谷肽胰岛素/阿斯巴甜胰岛素的疗效比较

IF 2.2

Diabetology International Pub Date : 2024-01-08 DOI: 10.1007/s13340-023-00681-7

J. Oya, Tomoko Nakagami, Y. Hasegawa, Yuichiro Kondo, Akihiko Katamine, Mika Shimizu, Ryo Kubota, Rika Suda, T. Babazono

引用次数: 0

Glycemic control and dementia risk in patients aged above and below 75 years 75 岁以上和 75 岁以下患者的血糖控制与痴呆症风险

IF 2.2

Diabetology International Pub Date : 2024-01-08 DOI: 10.1007/s13340-023-00684-4

Hae Hyuk Jung

引用次数: 0

Biomarkers and signaling pathways of diabetic nephropathy and peripheral neuropathy: possible therapeutic intervention of rutin and quercetin 糖尿病肾病和周围神经病变的生物标记物和信号通路：芦丁和槲皮素可能的治疗干预作用

IF 2.2

Diabetology International Pub Date : 2023-12-19 DOI: 10.1007/s13340-023-00680-8

Tamsheel F. Roohi, S. Mehdi, Sadaf Aarfi, K. L. Krishna, Suman Pathak, Seikh Mohammad Suhail, Syed Faizan

引用次数: 0